EMA Reviews Janssen’s Balversa for Advanced Urothelial Carcinoma with FGFR3 Alterations
The European Medicines Agency (EMA) has accepted for review a filing made by the Janssen...
J&J
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...
Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...
Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...
Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...
AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...
European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma
The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar
US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...
Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority
United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...